Welcome to our dedicated page for Neurosense Therapeutics news (Ticker: NRSN), a resource for investors and traders seeking the latest updates and insights on Neurosense Therapeutics stock.
NeuroSense Therapeutics Ltd (NRSN) is a clinical-stage biotechnology company advancing therapies for neurodegenerative diseases, with a primary focus on Amyotrophic Lateral Sclerosis (ALS). This news hub provides investors and stakeholders with timely updates on PrimeC development, clinical trial progress, and strategic initiatives.
Access consolidated, verified information about NRSN's scientific advancements including Phase 2b trial results, regulatory submissions, and intellectual property milestones. Our repository features press releases covering clinical data analyses, partnership announcements, and biomarker research developments specific to ALS pathology.
Key updates include progress on PrimeC's extended-release formulation, patent grants for combination therapies, and FDA/Health Canada regulatory interactions. Bookmark this page for objective reporting on trial enrollment status, peer-reviewed publication alerts, and neurodegenerative treatment innovations.
NeuroSense Therapeutics (Nasdaq: NRSN) has received a delisting notice from Nasdaq due to non-compliance with the minimum $2,500,000 stockholders' equity requirement, as per Listing Rule 5550(b). The company must request a hearing before a Nasdaq Hearings Panel to stay the delisting process. NeuroSense plans to present its compliance strategy during the hearing. The Panel can grant an extension until December 18, 2024, for the company to meet the equity requirement and maintain its listing status.
NeuroSense Therapeutics (NASDAQ: NRSN) announced that its VP of R&D, Dr. Shiran Zimri, will present at the 3rd Annual ALS Drug Development Summit in Boston on May 22, 2024. Dr. Zimri will discuss the potentials of combination therapy in ALS and share the latest progress on PrimeC, NeuroSense's investigational treatment. Recent results from the phase 2b PARADIGM trial showed a 43% slowing of disease progression in high-risk ALS patients treated with PrimeC compared to placebo over 6 months, with a significant 5.04-point difference in ALSFRS-R scores.
NeuroSense Therapeutics (Nasdaq: NRSN) has partnered with PhaseV to optimize its Phase 3 trial of PrimeC for ALS using advanced causal machine learning. PhaseV's analysis of NeuroSense's PARADIGM Phase 2b study predicted high success probabilities in multiple subgroups for the Phase 3 trial. PhaseV's insights will inform study design, patient enrollment, and cost-effectiveness. NeuroSense’s recent Phase 2b data showed PrimeC slowed disease progression by 37% and 43% in high-risk patients. The company plans to submit its End of Phase 2 package to the FDA and EMA soon.
NeuroSense Therapeutics announces positive data analysis from the PARADIGM clinical trial, showing a 43% slowing of disease progression in high-risk ALS patients treated with PrimeC. The study demonstrated consistent results across subgroups, indicating the potential of PrimeC to redefine ALS treatment. The CEO expressed optimism and highlighted the significant impact of PrimeC on patients, with plans to use the data for the upcoming pivotal trial.
NeuroSense Therapeutics (Nasdaq: NRSN) provides a business update for Q1 2024, highlighting key collaborations and positive results from the PARADIGM Study in ALS and Alzheimer's disease. The company is focused on advancing its treatments for neurodegenerative diseases, with plans for further research and clinical trials in the coming months.
FAQ
What is the current stock price of Neurosense Therapeutics (NRSN)?
What is the market cap of Neurosense Therapeutics (NRSN)?
